Document:

Exhibit 10.5

 

THIS WARRANT AND THE SHARES
ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES
LAWS OF ANY STATE, AND ARE SUBJECT TO CERTAIN INVESTMENT REPRESENTATIONS, AND MAY NOT BE SOLD, PLEDGED, OFFERED FOR SALE, OR OTHERWISE
TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION UNDER THE ACT AND SUCH APPLICABLE STATE SECURITIES LAWS, OR AN OPINION
OF COUNSEL SATISFACTORY TO NUGENE INTERNATIONAL, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.

 

	WARRANT TO PURCHASE COMMON STOCK

 

		Corporation:	NUGENE INTERNATIONAL, INC. (“NuGene”)

		Number of Shares:	Determined
in Accordance With Article I, Below

		Class of Stock:	Common

		Initial Exercise Price:	Seventy
One Cents ($0.71) (closing price of NuGene common stock on the Issue Date)

		Issue Date:	22
September 2016

		Expiration Date:	25
September 2026

 

I

GRANT OF WARRANT AND WARRANT SHARES

 

M. SAEED KHARAZMI,
or his duly designated assignee (“Holder”), is entitled to purchase that number of fully paid and nonassessable
shares of common stock of NuGene (the “Warrant Shares”) determined as follows:

 

During and throughout
the first 24-months immediately following the Issue Date (the “Non-Dilute Term”), the Warrant Shares shall be
equal to the greater of (i) one million (1,000,000) shares; or, (ii) two and one-half percent (2.5%) of the issued and outstanding
common shares of NuGene, determined on an as if converted and issued basis. Upon the expiration of the Non-Dilute Term, the Warrant
Shares shall be fixed in accordance with the above formula, and such number of Warrant Shares shall remain at that number up to
and until the Expiration Date.

 

The initial exercise price per share (the
“Warrant Price”) is set forth above, subject to adjustment pursuant to Article III of this Warrant to
Purchase Common Stock (the “Warrant”). This Warrant is issued pursuant to that certain Employment Agreement
by and between NuGene and Holder (the “Employment Agreement”).

 

II

EXERCISE

 

2.1           Method
of Exercise. Holder may exercise this Warrant, in whole or on part, at any time or times on or after the Issue Date and
on or before the Expiration Date by delivery of a duly executed Notice of Exercise Form, attached as Exhibit 2.1, to NuGene at
the principal office of NuGene (or such other office or agency of NuGene as it may designate by notice in writing to the registered
Holder at the address of such Holder appearing on the books of NuGene). Holder shall also deliver to NuGene, within five (5) business
days of the date said Notice of Exercise is delivered to NuGene, payment of the aggregate Warrant Price for the Warrant Shares
purchased (the “Exercise Price”), with payment by wire transfer or cashier’s check, or as cashless exercise
under Section 2.2, below.

 

    	 	1	 

     

    

 

 

2.2          Cashless
Exercise. This Warrant may also be exercised at such time by means of a “cashless exercise” in which Holder
shall be entitled to receive a certificate for the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)]
by (A), where:

 

		(A) =	the closing price of NuGene common stock on the Trading
Day immediately preceding the date of such election;

 

		(B) =	the Exercise Price of this Warrant, as adjusted; and

 

		(X) =	the number of Warrant Shares issuable upon exercise of this Warrant in accordance with the terms
of this Warrant by means of a cash exercise rather than a cashless exercise.

 

Notwithstanding anything herein to the
contrary, on the Expiration Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section
2.2.

 

2.3          Mechanics
of Exercise.

 

2.3.1.          Authorization
of Warrant Shares. NuGene covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be duly authorized, validly
issued, fully paid, and nonassessable and free from all taxes, liens, and charges in respect of the issue thereof (other than taxes
in respect of any transfer occurring contemporaneously with such issue).

 

2.3.2.          Delivery
of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the transfer agent
of NuGene to Holder by crediting the account of the Holder’s prime broker with the Depository Trust Company through its
Deposit Withdrawal Agent Commission (“DWAC”) system if NuGene is a participant in such system, and otherwise
by physical delivery to the address specified by Holder in the Notice of Exercise within five (5) business days from the receipt
by NuGene of the Notice of Exercise Form, surrender of this Warrant, and payment of the aggregate Exercise Price or cashless exercise.
This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by NuGene, or delivery of the Notice
of Exercise Form in the case of a cashless exercise. The Warrant Shares shall be deemed to have been issued, and Holder or any
other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes,
as of the date the Warrant has been exercised by payment to NuGene of the Exercise Price (or cashless exercise) and all taxes
required to be paid by the Holder, if any, pursuant to Section 2.3.5., below, prior to the issuance of such shares, have been
paid.

 

2.3.3.          Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, NuGene shall, at the time of delivery
of the certificate or certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder
to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical
with this Warrant.

 

    	 	2	 

     

    

  

2.3.4.          No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, NuGene
shall pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price.

 

2.3.5.          Charges,
Taxes, and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue
or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall
be paid by NuGene, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed
by Holder. However, that in the event certificates for Warrant Shares are to be issued in a name other than the name of
the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed
by the Holder; and NuGene may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer
tax incidental thereto.

 

2.3.6.          Closing
of Books. NuGene will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.

 

2.4          Replacement
of Warrants. On receipt of evidence reasonably satisfactory to NuGene of the loss, theft, destruction or mutilation of
this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in
form and amount to NuGene or, in the case of mutilation, or surrender and cancellation of this Warrant, NuGene at its expense
shall execute and deliver, in lieu of this Warrant, a new warrant, which new warrant shall in all respects be identical with this
Warrant.

 

2.5          Assumption
of Warrant. Upon the closing of any Acquisition the successor entity shall assume the obligations of this Warrant, and
then this Warrant shall be exercisable for the same securities, cash, and property as would be payable for the Warrant Shares issuable
upon exercise of the unexercised portion of this Warrant as if such Warrants Shares were outstanding on the record date for the
Acquisition and subsequent closing. For the purpose of this Warrant, “Acquisition” means any sale, license,
or other disposition of all or substantially all of the assets (including intellectual property) of NuGene, or any reorganization,
consolidation, or merger of NuGene where the holders of NuGene’s securities before the transaction beneficially own less
than fifty percent (50%) of the outstanding voting securities of the surviving entity after the transaction.

 

2.6          Term.
This Warrant and all rights hereunder shall expire on the 25th day of September, 2026.

 

III

ADJUSTMENTS TO THE WARRANT SHARES

 

3.1          Stock
Dividends, Splits, Etc. If NuGene (i) declares or pays a dividend on its common stock payable in common stock or other
securities, or (ii) declares a stock split, then upon exercise of this Warrant, the number of Warrant Shares to be acquired hereunder
shall be adjusted to reflect the action taken under this Section 3.1, meaning that Holder shall be treated as if Holder owned the
Warrant Shares of record as of the date the dividend or stock split occurred.

 

    	 	3	 

     

    

  

3.2           Reclassification,
Exchange, or Substitution. Upon any reclassification, exchange, substitution, or other event that results in a change of
the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive,
upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received for
the Warrant Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution, or other
event. NuGene or its successor shall promptly issue to Holder a new Warrant for such new securities or other property. The new
Warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for
in this Article II including, without limitation, adjustments to the Warrant Price and to the number of securities or property
issuable upon exercise of the new Warrant. The provisions of this Section 3.2 shall similarly apply to successive reclassifications,
exchanges, substitutions, or other events.

 

3.3           No
Impairment. NuGene shall not, by amendment of its Articles of Incorporation or through a reorganization, transfer of assets,
consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed under this Warrant by NuGene, but shall at all times in good faith
assist in carrying out all the provisions of this Article III and in taking all such action as may be necessary or appropriate
to protect Holder’s rights under this Article III against impairment.

 

IV

ADDITIONAL COVENANTS AND OBLIGATIONS

 

4.1           Notice
of Certain Events. If NuGene proposes at any time (a) to declare any dividend or distribution upon its common stock,
whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription
pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or other rights;
(c) to effect any reclassification or recapitalization of common stock; (d) to merge or consolidate with or into any
other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate, dissolve or wind
up; or (e) offer holders of registration rights the opportunity to participate in an underwritten public offering of the company’s
securities for cash, then, in connection with each such event, NuGene shall give Holder (1) at least five (5) days prior written
notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the
date on which the holders of common stock will be entitled thereto) or for determining rights to vote, if any, in respect of the
matters referred to in (a) and (b) above; (2) in the case of the matters referred to in (c) and (d) above at least five (5)
days prior written notice of the date when the same will take place (and specifying the date on which the holders of common stock
will be entitled to exchange their common stock for securities or other property deliverable upon the occurrence of such event);
and (3) in the case of the matter referred to in (e) above, the same notice as is given to the holders of such registration
rights.

 

4.2           Registration.
Holder shall have the right to require NuGene to register the Warrant Shares pursuant to any S-8 registration statement filed by
NuGene.

 

4.3           Transferability.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4.4, below, this Warrant and
all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of NuGene, together
with a written assignment of this Warrant substantially in the form of Exhibit 4.3, attached hereto, duly executed by Holder or
its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, NuGene shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. A Warrant, if properly assigned,
may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

    	 	4	 

     

    

  

4.4           Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws, NuGene may require, as a condition of allowing such transfer (i) that the Holder or transferee
of this Warrant, as the case may be, furnish to NuGene a written opinion of counsel (which opinion shall be in form, substance
and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration
under the Securities Act and under applicable state securities or blue sky laws, (ii) that the holder or transferee execute and
deliver to NuGene an investment letter in form and substance acceptable to NuGene and (iii) that the transferee be an “accredited
investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or (a)(8) promulgated under the Securities Act or a qualified
institutional buyer as defined in Rule 144A(a) under the Securities Act.

 

4.5           No
Rights as Shareholder Until Exercise. This Warrant does not entitle Holder to any voting rights or other rights as a shareholder
of NuGene prior to the exercise hereof. Upon the surrender of this Warrant and the payment of the aggregate Exercise Price (or
by means of a cashless exercise), the Warrant Shares so purchased shall be and be deemed to be issued to such Holder as the record
owner of such shares as of the close of business on the later of the date of such surrender or payment.

 

4.6           Title
to Warrant. Prior to the Expiration Date and subject to compliance with applicable laws and this Warrant, this Warrant
and all rights hereunder are transferable, in whole or in part, at the office or agency of
NuGene by the Holder in person or by duly authorized attorney, upon surrender of this Warrant together with the Assignment Form
annexed hereto properly endorsed. The transferee shall sign an investment letter in form and substance reasonably satisfactory
to NuGene.

 

4.7           Limitation
of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant or purchase
Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for
the purchase price of any Warrant Shares or as a stockholder of NuGene, whether such liability is asserted by NuGene or by creditors
of NuGene.

 

4.8           Compliance
with Securities Laws on Transfer. This Warrant and the Warrant Shares issuable upon exercise this Warrant (and the securities
issuable, directly or indirectly, upon conversion of the Warrant Shares, if any) may not be transferred or assigned in whole or
in part without compliance with applicable federal and state securities laws by the transferor and the transferee.

 

4.9           Limitation
of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for
the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or
by creditors of the Company.

 

    	 	5	 

     

    

  

V

ADDITIONAL PROVISIONS 

 

The provisions of Article
IX of the Employment Agreement are hereby incorporated by reference as if set forth in full herein.

 

VI

EXECUTION

 

IN WITNESS WHEREOF,
this WARRANT TO PURCHASE COMMON STOCK has been duly executed by the Parties and shall be effective as of and on the Issue Date.
Each of the undersigned Parties hereby represents and warrants that it (i) has the requisite power and authority to enter into
and carry out the terms and conditions of this Warrant, as well as all transactions contemplated hereunder; and, (ii) it is duly
authorized and empowered to execute and deliver this Warrant.

 

	NUGENE:	HOLDER:	 
	 	 	 	 
	NUGENE INTERNATIONAL, INC.,	 	 
	a Nevada corporation	/s/ M. Saeed Kharazmi	 
	 	 	 	M. SAEED KHARAZMI
	 	 	 	 
	BY:	/s/ Ali Kharazmi	 	DATED: 22 September 2016
	 	 	 	 	 
	NAME:	Ali Kharazmi	 	 
	 	 	 	 
	TITLE:	Chairman	 	 
	 	 	 	 
	DATED: 	22 September 2016	 	 

  

    	 	6	 

     

    

 

EXHIBIT 1.1

 

NOTICE OF EXERCISE

 

To:         NUGENE
INTERNATIONAL, INC.

 

(1)          The
undersigned hereby elects to purchase ________ Warrant Shares of NuGene pursuant to the terms of the attached Warrant, and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)           Payment
shall take the form of (check applicable box):

 

 ̈         enclosed
check;

 

 ̈         wire
transfer; or

 

 ̈         cashless
exercise.

 

(3)         Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is
specified below:____________________________________________.

 

(4)         The
Warrant Shares shall be delivered to the following address:

 

__________________________________________

__________________________________________

__________________________________________

 

(5)         The
undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as
amended.

 

	 	__________________________
	 	NAME: _______________________
	 	DATED: ______________________

 

IF INVESTING ENTITY IS DIFFERENT FROM HOLDER:

 

	 	Name of Investing Entity:	__________________________________________	 
	 	 	 	 
	 	Form of Entity:	__________________________________________	 
	 	 	 	 
	 	State of Formation/Residency:	__________________________________________	 
	 	 	 	 
	 	EIN/SSN:	__________________________________________	 

 

 

	 	BY: __________________________
	 	 
	 	NAME: _______________________
	 	 
	 	TITLE: _______________________
	 	 
	 	DATED: ______________________

 

    	 	7	 

     

    

  

EXHIBIT 3.3

 

ASSIGNMENT FORM

 

TO ASSIGN THE WARRANT, EXECUTE THIS FORM
AND SUPPLY THE REQUIRED INFORMATION.

DO NOT USE THIS FORM TO EXERCISE THE WARRANT

 

FOR VALUE RECEIVED,
the foregoing Warrant and all rights evidenced thereby are hereby assigned to _______________________________________________,
whose address is ______________________________________________________________________________.

 

	 	BY: __________________________
	 	 
	 	NAME: _______________________
	 	 
	 	TITLE: _______________________
	 	 
	 	DATED: ______________________

 

Signature Guaranteed: ___________________________________________

 

NOTE: The signature to this Assignment
Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever,
and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative
capacity should file proper evidence of authority to assign the foregoing Warrant.

 

    	 	8Exhibit 10.6

 

NUGENE
INTERNATIONAL, INC.

RESTRICTED
STOCK UNITS AGREEMENT

 

THIS RESTRICTED
STOCK UNITS AGREEMENT (the “Agreement”) is made and entered into as of the 22nd day
of September, 2016 (the “Grant Date”), by and between NUGENE INTERNATIONAL, INC., a Nevada corporation
(the “Company”); and, M. SAEED KHARAZMI (the “Grantee”), the Company’s Chief Medical
Officer and Vice-Chairman of the Company’s Board of Directors. The Company has granted to the Grantee an award (the “Award”)
consisting of two million (2,000,000) Restricted Stock Units (the “Total Number of Units”), subject to
the terms and conditions of this Agreement. Each Unit represents a right to receive upon settlement one (1) share of Stock.
The Award has not been granted pursuant to any compensatory, bonus, or similar plan maintained or otherwise sponsored by the Company
(collectively, the “Plan”), and the shares of Stock that may become issuable upon settlement the Units shall
not reduce the number of shares of Stock available for issuance under any Plan. The Company and Grantee are sometimes referred
to collectively herein as the “Parties”, and each individually as a “Party”.

 

1.     DEFINITIONS
AND INTERPRETATION.

 

1.1           Definitions.
In addition to other capitalized terms defined elsewhere in this Agreement, the following capitalized terms shall have the following
meanings:

 

“Board” means
the Board of Directors of the Company. If one or more committees of the Board of Directors have been appointed by the Board to
administer this Agreement, “Board” also means such committee(s).

 

“Cause” shall
have the same meaning as under the Employment Agreement executed concurrently by and between the Parties (the “Employment
Agreement”).

 

“Change in
Control” shall have the same meaning as under the Employment Agreement.

 

“Code” means
the Internal Revenue Code of 1986, as amended, and any applicable regulations and administrative guidelines promulgated thereunder.

 

“Complete
Disability” shall have the same meaning as under the Employment Agreement.

 

“Dividend
Equivalent Units” mean additional Restricted Stock Units credited pursuant to Section 2.3, below.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“Expiration
Date” means the seventh (7th) anniversary of the Grant Date.

 

“Fair Market
Value” means as of any date, the value of a share of Stock or other property as determined by the Board, in
its discretion, or by the Company, in its discretion, if such determination is expressly allocated to the Company herein, subject
to the following:

 

    	 	1	 

     

    

 

 

(a)   If,
on such date, the Stock is listed or quoted on a national or regional securities exchange or quotation system, the Fair Market
Value of a share of Stock shall be the closing price of a share of Stock as quoted on the national or regional securities exchange
or quotation system constituting the primary market for the Stock, as reported in The Wall Street Journal or such
other source as the Board deems reliable. If the relevant date does not fall on a day on which the Stock has traded on such securities
exchange or quotation system, the date on which the Fair Market Value shall be established shall be the last day on which the Stock
was so traded or quoted prior to the relevant date, or such other appropriate day as shall be determined by the Board, in its discretion.

 

(b)   If,
on such date, the Stock is not listed or quoted on a national or regional securities exchange or quotation system, the Fair Market
Value of a share of Stock shall be as determined by the Board in good faith without regard to any restriction other than a restriction
which, by its terms, will never lapse.

 

“Participating
Company” means the Company and any subsidiary of the Company.

 

“Restricted
Stock Unit” or “Unit” means a right to receive on the applicable Settlement
Date and in accordance with this Agreement one (1) share of Stock, and includes the Total Number of Units originally granted
pursuant to this Agreement and the Dividend Equivalent Units credited pursuant to Section 2.3, as both may be adjusted from
time to time pursuant to Section 7.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

“Service” means
the Grantee’s service to the Company as a director or consultant. The Grantee’s Service shall not be deemed to have
been interrupted or terminated if the Grantee takes any sick leave, or other bona fide leave of absence approved by the Company’s
Board of Directors.

 

“Service
Condition” means the condition to the vesting of the Award. The Service Condition is satisfied based on the
duration of the Grantee’s continuous Service from the Grant Date, as provided by Section 3.1.

 

“Settlement
Date” means, for each Vested Unit, the earliest of (i) the six-month anniversary of the date the Service
Condition is satisfied with respect to such Vested Unit (or, at the sole discretion of the Board, at such later date during the
same calendar year); (ii) the date the Grantee’s Service ceases for any reason and such cessation constitutes a “separation
from service” within the meaning of Section 409A of the Code; or (iii) the date of a Change in Control that constitutes
a “change in control event” within the meaning of Section 409A of the Code.

 

“Stock” means
the common stock of the Company, subject to adjustment as provided by Section 7.

 

“Trading
Compliance Policy” means the written policy of the Company pertaining to the purchase, sale, transfer or other
disposition of the Company’s equity securities by directors, officers, employees or other service providers who may possess
material, nonpublic information regarding the Company or its securities.

 

“Vested Unit” means
a Unit that has vested in accordance with Section 3 and ceased to be subject to the Company Reacquisition Right described
in Section 4.1.

 

    	 	2	 

     

    

  

1.2           Interpretation.

 

1.2.1.          Provision
Not Construed Against Drafting Party. This Agreement is the result of negotiations by and between the Parties, and each
Party has had the opportunity to be represented by independent legal counsel of its choice. This Agreement is the product of the
work and efforts of all Parties, and shall be deemed to have been drafted by all Parties. In the event of a dispute, no Party shall
be entitled to claim that any provision should be construed against any other Party by reason of the fact that it was drafted by
one particular Party.

 

1.2.2.          Agreement
Provisions, Exhibits, and Schedules. When a reference is made in this Agreement to an Article, Section, Subsection, Exhibit,
or Schedule, such reference shall be to said item of this Agreement unless otherwise indicated. The Exhibits and Schedules identified
in this Agreement are incorporated herein by reference and made a part hereof as if set out in full herein.

 

1.2.3.          Entire
Agreement. This Agreement, and all references, documents, or instruments referred to herein, contains the entire agreement
and understanding of the Parties in respect to the subject matter contained herein. The Parties have expressly not relied upon
any promises, representations, warranties, agreements, covenants, or undertakings, other than those expressly set forth or referred
to herein. This Agreement supersedes (i) any and all prior written or oral agreements, understandings, and negotiations between
the Parties with respect to the subject matter contained herein; and, (ii) any course of performance and/or usage of the trade
inconsistent with any of the terms hereof.

 

1.2.4.          Severability.
Each and every provision of this Agreement is severable and independent of any other term or provision of this Agreement. If any
term or provision hereof is held void or invalid for any reason by a court of competent jurisdiction, such invalidity shall not
affect the remainder of this Agreement.

 

1.2.5.          Successors
and Assigns. Except as expressly provided in this Agreement, each and all of the covenants, terms, provisions, conditions,
and agreements herein contained shall be binding upon and shall inure to the benefit of the successors and assigns of the Parties.

 

1.2.6.          Time.
All Parties agree that time is of the essence as to this Agreement.

 

1.2.7.          Governing
Law. This Agreement shall be governed by the laws of the State of California, without giving effect to any choice or conflict
of law provision or rule (whether of the State of California or any other jurisdiction) that would cause the application of the
laws of any jurisdiction other than the State of California. If any court action is necessary to enforce the terms and conditions
of this Agreement, the Parties hereby agree that the Superior Court of California, County of Orange, shall be the sole jurisdiction
and venue for the bringing of such action.

 

1.3           Additional
Definitions and Interpretation Provisions. For purposes of this Agreement, (i) those words, names, or terms which are specifically
defined herein shall have the meaning specifically ascribed to them; (ii) wherever from the context it appears appropriate, each
term stated either in the singular or plural shall include the singular and plural; (iii) wherever from the context it appears
appropriate, the masculine, feminine, or neuter gender, shall each include the others; (iv) the words “hereof”, “herein”,
“hereunder”, and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole, and
not to any particular provision of this Agreement; (v) all references to “Dollars” or “$” shall be construed
as being United States Dollars; (vi) the term “including” is not limiting and means “including without limitation”;
and, (vii) all references to all statutes, statutory provisions, regulations, or similar administrative provisions shall be construed
as a reference to such statute, statutory provision, regulation, or similar administrative provision as in force at the date of
this Agreement and as may be subsequently amended.

 

    	 	3	 

     

    

  

2.     THE
AWARD.

 

2.1           Grant
of Units. On the Grant Date, the Grantee shall acquire, subject to the provisions of this Agreement, the Total Number
of Units, subject to adjustment as provided in Section 7. Each Unit represents a right to receive one (1) share of Stock
on the applicable Settlement Date and in accordance with this Agreement.

 

2.2           No
Monetary Payment Required. The Grantee is not required to make any monetary payment (other than applicable tax withholding,
if any) as a condition to receiving the Units or shares of Stock issued upon the vesting or settlement of the Units, the consideration
for which shall be services to be rendered to a Participating Company or for its benefit. Notwithstanding the foregoing, if required
by applicable law, the Grantee shall furnish consideration in the form of cash or past services rendered to a Participating Company
or for its benefit having a value not less than the par value of the shares of Stock issued upon settlement of the Units.

 

2.3           Dividend
Equivalent Units. On the date that the Company pays a cash dividend or other cash distribution to holders of Stock
generally, the Grantee shall be credited with a number of additional whole Dividend Equivalent Units determined by dividing (a) the
product of (i) the dollar amount of the cash dividend or distribution paid per share of Stock on such date and (ii) the
total number of Units previously credited to the Grantee pursuant to this Agreement which have not been settled or forfeited pursuant
to the Company Reacquisition Right (as defined below) as of such date, by (b) the Fair Market Value per share of Stock on
such date. Any resulting fractional Dividend Equivalent Unit shall be rounded to the nearest whole number. Such additional Dividend
Equivalent Units shall be subject to the same terms and conditions and shall be settled or forfeited in the same manner and at
the same time as the Units originally subject to this Agreement with respect to which they have been credited.

 

2.4           Termination
of the Award. The Award shall terminate upon the first to occur of (a) the final settlement of all Vested Units
in accordance with Section 5 (including a final settlement upon the cessation of Grantee’s Services) or (b) the
Expiration Date if settlement has not occurred on or before the Expiration Date.

 

3.     VESTING
OF UNITS.

 

3.1           Satisfaction
of Service Condition. Except as provided by Section 3.2 below and subject to the Grantee’s continuous Service
through the applicable date set forth in the table below (each a “Service Date”), the Service Condition will
be satisfied in accordance with the following schedule:

 

	Service Date	 	Percentage of Units	 
	 	 	 	 
	22 September 2017	 	 	33.34	%
	22 September 2018	 	 	33.33	%
	22 September 2019	 	 	33.33	%

 

    	 	4	 

     

    

  

3.2          Vesting
Upon Change in Control or Upon Removal Without Cause or Due to Death, or Complete Disability. Upon the Occurrence
of a Change in Control, the Service Condition will be satisfied with respect to one-hundred percent (100%) of the Total Number
of Units effective as of the date of such Change in Control. If the Grantee’s Service is involuntarily ceased by the Company
for any reason other than Cause or the Grantee’s Service ends as a result of the Grantee’s death or Complete Disability,
then the Service Condition will be satisfied with respect to one-hundred percent (100%) of the Total Number of Units effective
as of the date of such end of Service. If the Grantee voluntarily terminates his Service there shall be no acceleration of the
Service Condition.

 

3.3          Effect
of the End of Service. Subject to the vesting provisions in Sections 3.1 and 3.2 above, upon the end of Grantee’s
Service (whether by the Company or by Grantee and whether for Cause or for any or no reason), then:

 

(a)   all
Units for which the Service Condition has not been satisfied as of the date of such end of Service shall be subject to
the Company Reacquisition Right (as defined in Section 4.1) immediately upon the end of Grantee’s Service; and

 

(b)   all
Units for which the Service Condition has been satisfied as of the date of such end of Service (including as a result
of Section 3.2) shall not be subject to the Company Reacquisition Right, but instead shall remain Vested Units.

 

3.4          Payments
Upon Vesting. On the day of Vesting of any Units pursuant to Section 3.1, above, the Company shall:

 

(a)   if
Grantee is an employee at the time of Vesting, withhold, on behalf of Grantee, the Federal Insurance Contributions Act tax imposed
pursuant to Sections 3101 and 3121(v)(2) of the Code on the Vested Units (the “FICA Amount”). In addition, the
Company shall pay Grantee an amount equal to the sum of (A) the FICA Amount, plus (B) a tax gross-up payment (computed
at the highest applicable marginal rate) in an amount that, after payment of all federal, state, and local income and employment
taxes, results in the Grantee’s receipt and retention, on an after-tax basis, of an amount equal to all federal, state, and
local taxes payable by Grantee on the FICA Amount.

 

(b)   if
Grantee is a director or consultant at the time of Vesting, pay Grantee an amount equal to the sum of (A) the taxes imposed
pursuant to Section 1401 of the Code on the Vested Units that are treated as “self-employment income” (as defined
in Section 1402(b) of the Code), plus (B) a tax gross-up payment (computed at the highest applicable marginal rate) in
an amount that, after payment of all federal, state, and local income and employment taxes, results in the Grantee’s receipt
and retention, on an after-tax basis, of an amount equal to all federal, state, and local taxes payable by Grantee on the amount
specified in Section 3.4(ii)(A).

 

The Company shall make any payments due
to Grantee pursuant to this Section 3.4 within 24 hours of the Vesting of any Units by wire transfer to the account designated
by Grantee.

 

    	 	5	 

     

    

  

3.5          Federal
Excise Tax Under Section 4999 of the Code.

 

3.5.1.          Excess
Parachute Payment. If any acceleration of vesting pursuant to the Award and any other payment or benefit (collectively,
the “Payments”) received or to be received by the Grantee would, but for this Section, subject the Grantee
to any excise tax pursuant to Section 4999 of the Code or any similar or successor provision (the “Excise Tax”)
due to the characterization of such acceleration of vesting, payment or benefit as an “excess parachute payment” under
Section 280G of the Code, then the aggregate amount of the Payments will be either fully payable or reduced to the largest
portion of the Payments that would result in no portion of the Payments (after reduction) being subject to the Excise Tax, whichever
results in the Grantee receiving the greatest amount of Payments, on an after-tax basis (accounting for federal, state, and local
income taxes and the Excise Tax), even if some or all of the Payments are subject to the Excise Tax. Any reduction in the Payments
required by this Section will be made in the following order: (i) reduction of cash payments; (ii) reduction of accelerated
vesting of equity awards other than stock options; (iii) reduction of accelerated vesting of stock options; and (iv) reduction
of other benefits paid or provided to the Grantee. In the event that acceleration of vesting of equity awards is to be reduced,
such acceleration of vesting will be cancelled in the reverse order of the date of grant of the Grantee’s equity awards.
If two or more equity awards are granted on the same date, each award will be reduced on a pro-rata basis.

 

3.5.2.          Determination
by Tax Firm. No later than the date of the occurrence of any event that might reasonably be anticipated to result
in an “excess parachute payment” to the Grantee, the Company shall request a determination in writing by the professional
firm engaged by the Company for general tax purposes, or, if the tax firm so engaged by the Company is serving as accountant or
auditor for the acquiror, the Company will appoint a regionally recognized tax firm to make the determinations required by this
Section (the “Tax Firm”). As soon as practicable thereafter, the Tax Firm shall determine the Grantee
the amount of such acceleration of vesting, payments and benefits to be reduced, if any. For the purposes of such determination,
the Tax Firm may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.
The Company and the Grantee shall furnish to the Tax Firm such information and documents as the Tax Firm may reasonably request
in order to make its required determination. The Company shall bear all reasonable fees and expenses the Tax Firm charges in connection
with its services contemplated by this Section.

 

4.     COMPANY
REACQUISITION RIGHT.

 

4.1           Grant
of Company Reacquisition Right. In the event that the Grantee’s Service ends for any reason, the Grantee shall
forfeit and the Company shall automatically reacquire all Units for which the Service Condition has not been satisfied as of the
time of such end of Grantee’s Service in accordance with Section 3 (the “Unvested Units”), and
the Grantee shall not be entitled to any payment therefor (the “Company Reacquisition Right”).

 

4.2           Dividends,
Distributions, and Adjustments. Upon the occurrence of a dividend or distribution to the stockholders of the
Company paid in shares of Stock or other property, or any other adjustment upon a change in the capital structure of the Company
as described in Section 7, any and all new, substituted or additional securities or other property to which the Grantee is
entitled by reason of the Grantee’s ownership of Unvested Units shall be immediately subject to the Company Reacquisition
Right and included in the terms “Units” and “Unvested Units” for all purposes of the Company Reacquisition
Right with the same force and effect as the Unvested Units immediately prior to the dividend, distribution or adjustment, as the
case may be. For purposes of determining the number of Units for which the Service Condition has been satisfied following a dividend,
distribution or adjustment, credited Service shall include all Service with any corporation which is a Participating Company at
the time the Service is rendered, whether or not such corporation is a Participating Company both before and after any such event.

 

    	 	6	 

     

    

 

5.     SETTLEMENT
OF THE UNITS.

 

5.1           Issuance
of Shares of Stock. Subject to the provisions of Section 5.3 below, the Company shall issue to the Grantee on
the Settlement Date with respect to each Vested Unit to be settled on such date one (1) share of Stock.

 

5.2           Beneficial
Ownership of Shares. A certificate for the shares acquired by the Grantee shall be registered in the name of the Grantee,
or, if applicable, in the names of the heirs of the Grantee.

 

5.3           Restrictions
on Grant of the Units and Issuance of Shares. As of the date of this Agreement, the grant of the Units and issuance
of shares of Stock upon settlement of the Units have not been registered under federal or state securities laws, and as a result,
shall be subject to compliance with all applicable requirements of federal, state or foreign law with respect to such securities.
No shares of Stock may be issued hereunder if the issuance of such shares would constitute a violation of any applicable federal,
state, or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which
the Stock may then be listed. The inability of the Company to obtain from any regulatory body having jurisdiction the authority,
if any, deemed by the Company’s legal counsel to be necessary to the lawful issuance of any shares subject to this Agreement
shall relieve the Company of any liability in respect of the failure to issue such shares as to which such requisite authority
shall not have been obtained. As a condition to the settlement of the Units, the Company may require the Grantee to satisfy any
qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation and to make any
representation or warranty with respect thereto as may be requested by the Company.

 

5.4           Transfer
of Shares. The Grantee may not transfer the shares of Stock issued upon settlement of the Units except in compliance
with applicable federal and state securities laws and the Company’s insider trading policy.

 

5.5           Fractional
Shares. The Company shall not be required to issue fractional shares upon the settlement of the Units.

 

6.     TAX
WITHHOLDING.

 

6.1           In
General. Grantee understands and agrees that the Grantee is an independent contractor and not an employee of the Company.
As a result, the Company will not make deductions for taxes from any amounts payable to Grantee as a result of his Services to
the Company or as a result of the vesting or settlement of the Units (except as otherwise specified in Section 3.4(i) or required
by applicable law or regulation). Any taxes imposed on the Grantee due to Services to the Company (including upon the issuance,
vesting and settlement of the Units) will be the sole responsibility of the Consultant (except as otherwise specified in Section 3.4(i)).

 

6.2           Cancellation
of Shares. The Company shall, upon request by the Grantee, allow Grantee to satisfy all or any portion of the Grantee’s
tax obligations upon the settlement of the Units by having the Company cancel the shares of Stock otherwise deliverable to the
Grantee in settlement of the Units in an amount equal to the number of whole shares having a fair market value, as determined by
the Company as of the date on which the tax obligations arise, not in excess of the amount of such tax obligations determined by
the applicable minimum statutory withholding rates. Upon cancellation of the shares, the Company shall pay the fair market value
of such cancelled shares to the Grantee in cash so that the Grantee can satisfy his tax obligations.

 

    	 	7	 

     

    

  

6.3           Notice
and Payment. On our before the date of each settlement of Units, the Grantee shall notify the Company of his election to
cancel shares of Stock pursuant to Section 6.2 upon the settlement of such Units. The Company shall make the payment due to
Grantee pursuant to Section 6.2 within 24-hours of the date of the settlement of the Units for which Grantee has elected to
cancel shares of Stock pursuant to Section 6.2 by wire transfer to the account designated by Grantee.

 

7.     ADJUSTMENTS
FOR CHANGES IN CAPITAL STRUCTURE. Subject to any required action by the stockholders of the Company and the requirements
of Section 409A of the Code to the extent applicable, in the event of any change in the Stock effected without receipt of
consideration by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification,
stock dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares, or
similar change in the capital structure of the Company, or in the event of payment of a dividend or distribution to the stockholders
of the Company in a form other than Stock (other than regular, periodic cash dividends paid on Stock pursuant to the Company’s
dividend policy) that has a material effect on the Fair Market Value of shares of Stock, appropriate and proportionate adjustments
shall be made in the number of Units subject to this Agreement and/or the number and kind of shares or other property to be issued
in settlement of the Units, in order to prevent dilution or enlargement of the Grantee’s rights under this Agreement. For
purposes of the foregoing, conversion of any convertible securities of the Company shall not be treated as “effected without
receipt of consideration by the Company.” Any and all new, substituted or additional securities or other property (other
than regular, periodic cash dividends paid on Stock pursuant to the Company’s dividend policy) to which the Grantee is entitled
by reason of ownership of Units acquired pursuant to this Agreement will be immediately subject to the provisions of this Agreement
on the same basis as all Units originally acquired hereunder. Any fractional Unit or share resulting from an adjustment pursuant
to this Section shall be rounded down to the nearest whole number. Such adjustments shall be determined by the Board, and its determination
shall be final, binding, and conclusive.

 

8.     RIGHTS
AS A STOCKHOLDER OR DIRECTOR. The Grantee shall have no rights as a stockholder with respect to any shares which may be
issued in settlement of the Units until the date of the issuance of such shares (as evidenced by the appropriate entry on the books
of the Company or of a duly authorized transfer agent of the Company). No adjustment shall be made for dividends, distributions
or other rights for which the record date is prior to the date the shares of Stock are issued, except as provided in Section 2.3
or Section 7. The Grantee understands and acknowledges that the Grantee’s Services to the Company is dictated by the
Employment Agreement. Nothing in this Agreement shall confer upon the Grantee any right to continue in the Service of a Participating
Company or interfere in any way with any right of a Participating Company to end the Grantee’s Service at any time.

 

9.     LEGENDS.
The Company may at any time place legends referencing any applicable federal, state or foreign securities law restrictions
on all certificates representing shares of stock issued pursuant to this Agreement. The Grantee shall, at the request of the Company,
promptly present to the Company any and all certificates representing shares acquired pursuant to this Agreement in the possession
of the Grantee in order to carry out the provisions of this Section. Unless otherwise specified by the Company, legends placed
on such certificates may include, but shall not be limited to, the following:

 

    	 	8	 

     

    

  

“THE SECURITIES EVIDENCED
BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED
OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH SECURITIES, THE SALE IS MADE IN
ACCORDANCE WITH RULE 144 OR RULE 701 UNDER THE ACT, OR THE COMPANY RECEIVES AN OPINION OF COUNSEL REASONABLY SATISFACTORY
TO THE COMPANY, STATING THAT SUCH SALE, TRANSFER, ASSIGNMENT OR HYPOTHECATION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY
REQUIREMENTS OF SUCH ACT.”

 

10.  COMPLIANCE
WITH SECTION 409A. The Parties intend that any election, payment, or benefit which is made or provided pursuant to or in
connection with this Agreement that may result in or relate to the deferral of compensation within the meaning of Section 409A
of the Code (“Section 409A Deferred Compensation”) shall comply in all respects with the applicable requirements
of Section 409A of the Code (including applicable regulations or other administrative guidance thereunder, as determined by
the Board in good faith) to avoid the unfavorable tax consequences provided therein for non-compliance. In connection with compliance
with Section 409A of the Code, the following shall apply:

 

10.1         Separation
from Service; Required Delay in Payment to Specified Grantee. Notwithstanding anything set forth herein to the contrary,
no amount payable pursuant to this Agreement on account of the Grantee’s end of Service which constitutes Section 409A
Deferred Compensation shall be paid unless and until the Grantee has incurred a “separation from service” within the
meaning of Section 409A of the Code. Furthermore, to the extent that the Grantee is a “specified employee” within
the meaning of the Section 409A as of the date of the Grantee’s separation from service, no amount that constitutes
a deferral of compensation which is payable on account of the Grantee’s separation from service shall be paid to the Grantee
before the date (the “Delayed Payment Date”) which is first day of the seventh month after the date of
the Grantee’s separation from service or, if earlier, the date of the Grantee’s death following such separation from
service. All such amounts that would, but for this Section, become payable prior to the Delayed Payment Date will be accumulated
and paid on the Delayed Payment Date.

 

10.2         Other
Changes in Time of Payment. Neither the Grantee nor the Company shall take any action to accelerate or delay the payment
of any benefits under this Agreement in any manner which would not be in compliance with Section 409A of the Code.

 

10.3         Amendments
to Comply with Section 409A; Indemnification. Notwithstanding any other provision of this Agreement to the contrary,
the Company is authorized to amend this Agreement, to void or amend any election made by the Grantee under this Agreement and/or
to delay the payment of any monies and/or provision of any benefits in such manner as may be determined by the Company, in its
discretion, to be necessary or appropriate to comply with Section 409A of the Code without prior notice to or consent of the
Grantee. The Grantee hereby releases and holds harmless the Company, its directors, officers and stockholders from any and all
claims that may arise from or relate to any tax liability, penalties, interest, costs, fees or other liability incurred by the
Grantee in connection with this Agreement, including as a result of the application of Section 409A of the Code.

 

    	 	9	 

     

    

  

10.4         Advice
of Independent Tax Advisor. The Company has not obtained a tax ruling or other confirmation from the Internal Revenue
Service with regard to the application of Section 409A to this Agreement, and the Company does not represent or warrant that
this Agreement will avoid adverse tax consequences to the Grantee, including as a result of the application of Section 409A
of the Code. The Grantee hereby acknowledges that he or she has been advised to seek the advice of his or her own independent tax
advisor prior to entering into this Agreement and is not relying upon any representations of the Company or any of its agents as
to the effect of or the advisability of entering into this Agreement.

 

11.   ADMINISTRATION.
All questions of interpretation concerning this Agreement or any other form of agreement or other document employed by the
Company in the administration of this Agreement shall be determined by the Board. All such determinations by the Board shall be
final, binding and conclusive upon all persons having an interest in this Agreement, unless fraudulent or made in bad faith. Any
and all actions, decisions, and determinations taken or made by the Board in the exercise of its discretion pursuant to this Agreement
or other agreement thereunder (other than determining questions of interpretation pursuant to the preceding sentence) shall be
final, binding, and conclusive upon all persons having an interest in this Agreement. Any officer of the Company shall have the
authority to act on behalf of the Company with respect to any matter, right, obligation, or election which is the responsibility
of or which is allocated to the Company herein, provided the officer has apparent authority with respect to such matter, right,
obligation, or election.

 

12.   REPRESENTATIONS
AND WARRANTIES OF THE GRANTEE. In connection with the acquisition of securities pursuant to this Agreement, the Grantee
hereby agrees, represents, and warrants as follows:

 

12.1         Investment
Intent. The Grantee is acquiring shares of Stock pursuant to this Agreement solely for the Grantee’s own account
for investment and not with a view to or for sale in connection with any distribution of the shares or any portion thereof and
not with any present intention of selling, offering to sell or otherwise disposing of or distributing the shares or any portion
thereof in any transaction other than a transaction exempt from registration under the Securities Act. The Grantee further represents
that the entire legal and beneficial interest of the shares is being acquired, and will be held, for the account of the Grantee
only and neither in whole nor in part for any other person.

 

12.2         Absence
of Solicitation. The Grantee was not presented with or solicited by any form of general solicitation or general advertising,
including, but not limited to, any advertisement, article, notice, or other communication published in any newspaper, magazine,
or similar media, or broadcast over television, radio or similar communications media, or presented at any seminar or meeting whose
attendees have been invited by any general solicitation or general advertising.

 

12.3         Capacity
to Protect Interests. The Grantee has either (a) a preexisting personal or business relationship with the Company
or any of its officers, directors, or controlling persons, consisting of personal or business contacts of a nature and duration
to enable the Grantee to be aware of the character, business acumen and general business and financial circumstances of the person
with whom such relationship exists, or (b) such knowledge and experience in financial and business matters (or has relied
on the financial and business knowledge and experience of the Grantee’s professional advisor who is unaffiliated with and
who is not, directly or indirectly, compensated by the Company or any affiliate or selling agent of the Company) as to make the
Grantee capable of evaluating the merits and risks of the investment in shares acquired pursuant to this Agreement and to protect
the Grantee’s own interests in the transaction, or (c) both such relationship and such knowledge and experience.

 

    	 	10	 

     

    

  

12.4        Restricted
Securities. The Grantee understands and acknowledges that:

 

(a)   The
issuance to Grantee of shares pursuant to this Agreement has not been registered under the Securities Act, and the shares must
be held indefinitely unless a transfer of the shares is subsequently registered under the Securities Act or an exemption from such
registration is available, and that the Company is under no obligation to register the shares; and

 

(b)   The
Company will make a notation in its records of the aforementioned restrictions on transfer and legends.

 

12.5         Disposition
Under Rule 144. The Grantee understands that if the shares acquired pursuant to this Agreement are not registered
prior to the Company’s issuance of such shares, the share will be restricted securities within the meaning of Rule 144 promulgated
under the Securities Act (“Rule 144”). In addition, Grantee understands that he is an “affiliate”
for purposes of Rule 144, and as such, remains subject to the “affiliate” restrictions set forth in Rule 144. As a
result, Grantee understands and agrees that any future transfers of the Stock must be conducted in compliance with Rule 144.

 

12.6         Reliance
by the Company. The Grantee understands that the shares acquired pursuant to this Agreement have not been registered
under the Securities Act or under applicable state securities laws by reason of specific exemptions therefrom, which exemptions
may depend upon, among other things, the bona fide nature of the Grantee’s representations as expressed herein. The Grantee
understands that the Company is relying on the Grantee’s representations and warrants that the Company is entitled to rely
on such representations and that such reliance is reasonable.

 

13.   ADDITIONAL
PROVISIONS.

 

13.1         Executed
Counterparts. This Agreement may be executed in any number of counterparts, all of which when taken together shall be considered
one and the same agreement, it being understood that all Parties need not sign the same counterpart. In the event that any signature
is delivered by Fax or by E-Mail, such signature shall create a valid and binding obligation of that Party (or on whose behalf
such signature is executed) with the same force and effect as an original thereof. Any photographic, photocopy, or similar reproduction
copy of this Agreement, with all signatures reproduced on one or more sets of signature pages, shall be considered for all purposes
as if it were an executed counterpart of this Agreement.

 

13.2         Enforcement.
The Parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed
in accordance with their specific terms or were otherwise breached. Accordingly, it is agreed that the Parties shall be entitled
to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions
of this Agreement, this being in addition to any other remedy to which they are entitled at law or in equity. The remedies of the
Parties under this Agreement are cumulative and shall not exclude any other remedies to which any person may be lawfully entitled.

 

13.3         Waiver.
No failure by any Party to insist on the strict performance of any covenant, duty, agreement, or condition of this Agreement or
to exercise any right or remedy on a breach shall constitute a waiver of any such breach or of any other covenant, duty, agreement,
or condition.

 

    	 	11	 

     

    

  

13.4        Recovery
of Fees by Prevailing Party. In the event of any legal action (including arbitration) to enforce or interpret the provisions
of this Agreement, the non-prevailing Party shall pay the reasonable attorneys’ fees, costs, and expenses (including expert
witness fees) of the prevailing Party in such amount as the court shall determine. In addition, such non-prevailing Party shall
pay reasonable attorneys’ fees incurred by the prevailing Party in enforcing, or on appeal from, a judgment in favor of the
prevailing Party. The preceding sentence is intended by the Parties to be severable from the other provisions of this Agreement
and to survive and not be merged into such judgment.

 

13.5        Termination
or Amendment. The Board may terminate or amend this Agreement at any time; provided, however, no such termination
or amendment may adversely affect the Grantee’s rights under this Agreement without the consent of the Grantee unless such
termination or amendment is necessary to comply with applicable law or government regulation, including, but not limited to, Section 409A
of the Code. No amendment or addition to this Agreement shall be effective unless in writing.

 

13.6        Nontransferability
of Units. Prior to the issuance of shares of Stock on the applicable Settlement Date, neither this Agreement nor any
Units subject to this Agreement shall be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment,
pledge, encumbrance, or garnishment by creditors of the Grantee or the Grantee’s beneficiary, except transfer by will or
by the laws of descent and distribution. All rights with respect to this Agreement shall be exercisable during the Grantee’s
lifetime only by the Grantee or the Grantee’s guardian or legal representative.

 

13.7        Further
Assurances. Each Party agrees (i) to furnish upon request to each other Party such further information; (ii) to
execute and deliver to each other Party such other documents; and, (iii) to do such other acts and things, all as another Party
may reasonably request for the purpose of carrying out the intent of this Agreement and the transactions envisioned hereunder.
However, this provision shall not require that any additional representations or warranties be made and no Party shall be
required to incur any material expense or potential exposure to legal liability pursuant to this Section 13.7.

 

13.8        Notices.

 

13.8.1.        Method
and Delivery. All notices, requests and demands hereunder shall be in writing and delivered by hand, by Electronic Transmission,
by mail, or by recognized commercial over-night delivery service (such as Federal Express or UPS), and shall be deemed given (a)
if by hand delivery, upon such delivery; (b) if by Electronic Transmission, upon telephone confirmation of receipt of same; (c)
if by mail, forty-eight (48) hours after deposit in the United States mail, first class, registered or certified mail, postage
prepaid; or, (d) if by recognized commercial over-night delivery service, upon such delivery.

 

13.8.2.          Consent
to Electronic Transmission. Each Party hereby expressly consents to the use of Electronic Transmission for communications
and notices under this Agreement. For purposes of this Agreement, “Electronic Transmission” means a communication
(i) delivered by Fax or E-Mail when directed to the Fax number or E-Mail address, respectively, for that recipient on record with
the sending Party; and, (ii) that creates a record that is capable of retention, retrieval, and review, and that may thereafter
be rendered into clearly legible tangible form.

 

    	 	12	 

     

    

  

13.8.3.          Address
Changes. Any party may alter the Fax number, E-Mail address, physical address, or postage address to which communications
or copies are to be sent by giving notice of such change of address to the other Parties in accordance with the provisions of this
Section 13.11.

 

13.9         Best
Efforts. Each Party shall cooperate in good faith with the other Parties generally, and in particular, the Parties shall
use and exercise their best efforts, taking all reasonable, ordinary and necessary measures to ensure an orderly and smooth relationship
under this Agreement, and further agree to work together and negotiate in good faith to resolve any differences or problems which
may arise in the future. However, the obligations under this Section 13.9 shall not include any obligation to incur substantial
expense or liability.

 

XIV

EXECUTION

 

IN WITNESS WHEREOF,
this RESTRICTED STOCK UNITS AGREEMENT has been duly executed by the Parties in Orange County, California, and shall be effective
as of and on the Grant Date. The Company hereby represents and warrants that it (i) has the requisite power and authority to enter
into and carry out the terms and conditions of this Agreement, as well as all transactions contemplated hereunder; and, (ii) it
is duly authorized and empowered to execute and deliver this Agreement.

 

	 	NUGENE:	 
	 	 	 
	 	NUGENE INTERNATIONAL, INC.,	 
	 	a Nevada corporation	 
	 	 	 	 
	 	 	 	 
	 	BY:  	/s/ Ali Kharazmi	 
	 	 	 	 
	 	NAME:  Ali Kharazmi	 
	 	 	 
	 	TITLE:  Chairman	 
	 	 	 
	 	DATED:  22 September 2016	 

 

XV

ACCEPTANCE

 

The Grantee represents
that the Grantee has read and is familiar with the terms and provisions of this Agreement and hereby accepts the Award subject
to all of the terms and provisions hereof. The Grantee hereby agrees to accept as binding, conclusive, and final all decisions
or interpretations of the Board of Directors of the Company upon any questions arising under this Agreement.

 

	DATED: 22 September 2016	/s/ M. Saeed Kharazmi	 
	 	M. SAEED KHARAZMI	 

 

    	 	13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]